Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

766 Features
Hypertension: excitement grows around Novartis hypertension franchise update in Big Apple

17 May 06

Despite almost 200 million people suffering from hypertension in the seven major pharmaceutical markets alone, according to a new report, innovation is scarce within antihypertensive R&D. What little innovation that does exist is being delivered by Novartis, which is set to launch two new antihypertensives in 2007 in the shape of oral renin inhibitor Rasilez, and the 'two-in-one' pill Exforge.
Datamonitor

VEGF: Same molecular target....new approaches to cancer

15 May 06

DailyUpdates 15th May, 2006: Amongst the 50 or so papers and press releases featured today two focusing on VEGF jump out as being of especial interest. The first, a paper published by Stanford University, reports on the anti-cancer activity of an oncolytic virus in combination with gene therapy. The virus was engineered to selectively replicate in and kill cancer cells . The gene therapy encoded a soluble version of Flk1, one of the VEGF receptors. The two approaches together produce effective a
LeadDiscovery

Leading by example: Amgen takes employee health seriously

15 May 06

When not doing 'insane sports', Amgen's Europe chief Rolf Hoffmann is battling big pharma
Katherine Griffiths

AVIAN FLU SUMMIT FOR BUSINESS

13 May 06

This summit aims to provide both strategic and practical information that will ensure that organisations can prepare for and survive what is now considered to be the inevitable pandemic. Professor Hugh Pennington from the Department of Medical Microbiology at University of Aberdeen will repeat his warning that, “Only one thing is certain and that is that there will be a pandemic.”
Susie Wilson

Movement in cancer vaccine development plus breaking antidepressant research

12 May 06

DailyUpdates 12th May, 2006 (click here for entire bulletin): Today appears to be cancer vaccine day with two important announements being made. First off, Genitope Corporation announce the initiation of an ealry phase clinical trial of their MyVax idiotype immunotherapy; this was followed by an announcement by Biovest reporting that fast track status had been awarded to their phase 3 candidate, BiovaxID. This follows in the footsteps of the company's announcement that the FDA had approved sale
LeadDiscovery

Adult acute leukemia: demand for innovative drugs that prolong survival

11 May 06

A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.
Datamonitor

The value of Marketing and PR in clinical research

10 May 06

Marketing and PR can play a variety of roles to support a company as it develops medicines in the modern healthcare setting. Therefore it is important that companies develop suitable Marketing and PR strategies to assist them in their business and understand how they can benefit from the tools used in these functions.
Dr Faiz Kermani

World Pharmaceutical (China) Summit 2006

10 May 06

This Conference will provide a platform for intellectual discourse in order to answer these questions and to discuss other pressing issues regarding the pharmaceutical industry in China in particular, and the world in general. Opportunities and challenges within the whole value chain, from research and development down to sales and marketing will be discussed and solutions put forward for the benefits of attendees.
IBG Company Limited

2nd Annual Specialty Pharmaceuticals Global Summit

25 Apr 06

Specialty Pharma transformations and venture investments have continued to grow at an unprecedented pace. The 2006 meeting is an elite opportunity for Big Pharma, Biotech, and Drug Delivery to network with the industry's fastest growing Specialty Pharma companies and discover what makes them so attractive as a partner.
Ed Drilon

17th International Contracting & Negotiating Clinical Trails

25 Apr 06

The Definitive Conference for Clinical Research Contract Professionals!
Glenn Pascual

Canada's Hidden Pharma Potential

06 Apr 06

Given its proximity to the huge US market, Canada is often overlooked with respect to its contribution to the pharmaceutical sector. Yet it is a well-established market in which all the major players are active and it has a vibrant R&D environment, both for traditional pharmaceutical companies and emerging biotech companies.
Dr Faiz Kermani

Mergers emerging in Japan

06 Apr 06

Japanese pharmaceutical companies have tended to avoid using mergers in their efforts to grow, but in recent times this attitude appears to have changed. Key mergers currently underway include Sankyo and Daiichi Pharmaceutical, Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical (who now operate as Astellas), and a tie-up between Dainippon Pharmaceutical and Sumitomo Pharmaceuticals.
Dr Faiz Kermani

China's Challenge to Pharma

06 Apr 06

China is a country that is rapidly modernising and as its economy grows its consumer base is changing. Many international biopharmaceutical companies have started to invest in China and believe that in the long-term the healthcare market offers huge commercial potential.
Dr Faiz Kermani

What is RSS

05 Apr 06

I recently ran a quick poll on PharmiWeb, to determine what level of awareness there was for RSS (really simple syndication). So...
Mike Wood

Search Engine Marketing Health Pharmaceutical Labs clinical

30 Mar 06

Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy.
Elias KAI

Study supports aggressive use of atorvastatin (Lipitor)

29 Mar 06

The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's atorvastatin/torcetrapib. Studies demonstrating that higher doses of existing products can offer improved efficacy but with no increase in side-effects will also help optimize sales in the antidyslipid
LeadDiscovery

Diagnosing acute congestive heart failure

28 Mar 06

Heart failure affects more than 5 million people in the U.S. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care system cost of $15 billion. Given the paucity of the pipeline for acute congestive heart failure, the best hope of clinical improvement will involve improved utilization of existing therapies. However early intervention requires rapid and accurate diagnosis. Given its diagnostic potential, the measurement of plasma BNP a
LeadDiscovery

PABORD 2006

27 Mar 06

The 2nd international exhibition and conference event focussed exclusively on the theme of outsourcing in the research and development of new medicines. Companies both large and small are adopting this increasingly popular business strategy.
ANDREW CLARK

6th Annual e-Clinical Trials

23 Mar 06

e-Clinical Trials continue to be used more and more by the market leaders - There is no doubt though that the industry is soon to go fully electronic, so don't get behind the game... Our delegates have been demanding we run this event for the last 6 years! Here is what they have said about our past events: "...one of the best. I have learned a great deal about many of the important issues associated with e-Clinical Trials", Clinical Trial Manager/EDC Liason, Forest Labs Inc. "Informatio
Amir Sebahat

Cdk5 inhibitors as novel candidate analgesics

22 Mar 06

According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004.  The pain market can be divided into acute pain which is well served by OTC medications, post-operative pain and chronic pain. One of the most challenging areas of analgesia is the treatment of chronic neuropathic pain.  Cancer pain also represents a largely unmet market which along with post-operative analgesia depends to a large extent on opioid-based th
LeadDiscovery

Pharma IQ announces inaugural event in Pharma Sales Force Effectiveness

21 Mar 06

If Sales Force Effectiveness is high on your agenda in the current climate, then don’t miss Pharma IQ’s Next Generation Pharmaceutical Sales Strategies event in June. Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.
Rachel Davis

Big Challenges For Pharma

06 Mar 06

Back in 2000, I was really, really excited. Had I got a date with Kylie Minogue? No. Had West Ham won the Champions League? Not likely. I was excited because I thought I had discovered the best investment sector in the market -- life sciences.
Ed Bowsher

Working for Merck Pharmaceuticals UK

03 Mar 06

PharmiWeb recently asked Merck to provide some insight into what it was like to work as a sales rep for their company. Rather than just telling us what they thought we wanted to hear, they took the more open approach of asking their team for "real life" comments, and then gave us their rather impressive raw responses, with no additions or changes.
Vincent Lody

Rituxan approval to mark a new era of B-cell targeted therapies of autoimmune disease?

01 Mar 06

Genentech and Biogen Idec announced yesterday that the FDA has approved Rituxan (Rituximab) for use as a treatment of rheumatoid arthritis. Hopefully this news will mark the start of a new era in the treatment of autoimmune disease.
LeadDiscovery

An Interview with Andrew Copestake Vice President - BD Europe

28 Feb 06

ICON’s core competency is project management, built up over the last fifteen years managing complex projects and underpinned by comprehensive and consistent processes which conform to the ISO9001:2000 quality certification.
Mike Wood

Abbott - Planning to Win

24 Feb 06

A glimpse of the broad-based, versatile business strategy that has enabled Abbott to combine dynamic growth with long-term stability.
Caroline Johnson

Abbott - Pipeline going from strength to strength

24 Feb 06

Abbott recently had the largest gain in reputation of any company in its industry when Fortune magazine ranked it number three in the magazine’s list of the most admired companies in the United States – Fortune’s highest ranking for Abbott since 1989. How was this achieved and what factors led up to it?
Caroline Johnson

Abbott - Global Citizenship

24 Feb 06

In an increasingly complex world, with significant changes taking place on a social, commercial and economic basis almost weekly, corporate social responsibility is a priority for Abbott as it engages its stakeholders, advances its core objectives and exercises its influence – making productive contribution to the societies and communities it operates in.
Caroline Johnson

NK1 receptor antagonists by Roche

23 Feb 06

In their study due to be published in the March edition of Bioorg Med Chem Lett, Hoffmann and colleagues from Roche describe the design of two promising NK1 receptor antagonists, netupitant and befetupitant.
LeadDiscovery

A novel therapeutic candidate for the treatment of lymphomas and other cancers

21 Feb 06

Today's edition of DailyUpdates features work conducted by Imperial College researchers who have identified an aptamer able to reduce the proliferation of lymphoma cells by 40%. This work represents a licensing opportunity. The aptamer is of potential therapeutic use and may be of interest to companies with an interest in biologic approach to oncology. The aptamers also forms the basis of a HTS assay that should help identify small molecule therapeutics for the treatment of hematological cancers
LeadDiscovery

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.